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Background: Primary fallopian tube carcinoma (PFTC) is rarely seen clinically. Herein, we investigate the clinical and
pathological characteristics and appropriate therapies for PFTC.
Methods: A total of 36 patients for whom PFTC was pathologically confirmed from January 2001 to July 2011 in
Beijing Hospital of Gynecology and Obstetrics, an affiliate of Capital Medical University, were retrospectively
analyzed.
Results: A total of 36 cases underwent surgical staging in our hospital: 47.2% were early stage cases , and 52.8%
were advanced stage cases. Of the 36 cases, 24 cases were pure adenocarcinoma, 10 cases were mixed, and there
was 1 case of undifferentiated carcinoma, 1 case of undifferentiated carcinoma combined with transitional cell
carcinoma, 5 cases of moderately differentiated carcinoma, and 29 cases of moderately to poorly differentiated
carcinoma. There were no cases of highly differentiated carcinoma. Among the cases examined, 38.9% (14/36) had
omentum metastasis, and 19 cases had an elevated CA125 during a preoperative biochemical laboratory test.
Approximately 35 cases received postoperative adjuvant chemotherapy. The 3-year and 5-year overall survival rates
for the 36 cases were 80.7% and 65.4%, respectively. Single-factor analysis showed that the pathological conditions
of residual tumor diameter >1 cm (P <0.001), omentum metastasis (P = 0.003), ovary metastasis (P = 0.004) and
elevated preoperative CA125 (P = 0.044) were associated with prognosis, whereas pathological surgical staging
(P = 0.069), retroperitoneal lymph node metastasis (P = 0.499), and pathological classification (P = 0.183) were not
associated with prognosis. Multifactor analysis showed that a residual tumor diameter >1 cm (P = 0.019) and
omentum metastasis (P = 0.015) were associated with prognosis, and were, therefore, the independent risk factors
of prognosis.
Conclusions: PFTC is a rare female genital tract malignancy. Most patients are in an advanced stage at diagnosis,
which results in a poor prognosis. Complete surgical staging and maximal resection should be recommended.
Keywords: Primary fallopian tube carcinoma, CA125, Risk factorsBackground
Fallopian tube cancer is a rare malignancy, accounting
for 0.5% of female genital cancer. It is divided into primary
and secondary carcinoma, of which secondary malignan-
cies are more often the results of metastasis of tubal ovar-
ian cancer or endometrial stumbled cancer [1]. Primary
fallopian tube carcinoma (PFTC) is rarely seen clinically
due to hidden lesions, an absence of recommended screen-
ing methods, and relatively limited clinical experience, to* Correspondence: duanwei6699@163.com
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unless otherwise stated.the extent that a number of cases have been accidentally
detected during other gynecological surgeries [2]. Because
the tubal wall has considerable flexibility, even if the tube
is filled with fluid or tumor, the tubal wall can still remain
quite complete. Intraluminal tubal fluid can be discharged
through the uterus-vagina route when fimbria atresia
occurs, and this is usually found in early cases. In case
of an open fimbrial end, the tumor cells would come
into the abdominal cavity where they could easily grow,
and this is found mostly in advanced cases, where the
prognosis is rather poor.
The etiology of this cancer is unknown. Hormonal, re-
productive, and possibly genetic factors thought to increasel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,




Age (years): Mean: 57.2, Range: 42 to 72
Menopause: 25 postmenopausal (69.4%)
Pathology: 9 postmenopausal vaginal bleeding or irregular
vaginal bleeding (25.0%)
12 vaginal discharge (33.3%)
9 abdominal distension or abdominal pain (25.0%)
1 back pain
4 asymptomatic yet with pelvic mass (11.1%)
1 poorly differentiated carcinoma
Preoperative screening: 28 preoperative cervical TCT 6 curettage
Surgical method: 1 left oophorectomy and partial omentum
resection
35 uterine double oophorectomy
31 pelvic an/or aortic lymph node dissection
35 full or partial omental resection
20 cytoreductive surgery
Adjuvant therapies:
Chemotherapy: 1 one-course preoperative neoadjuvant
chemotherapy
35 four- to eight-course postoperative
chemotherapy
31 TP
4 cisplatin and PC, or cisplatin, PC and PAC
Radiotherapy: 1 radiotherapy after six-course chemotherapy
Abbreviation: TCT thinpprep cytology test, TP taxol and cisplatin, PC cisplatin
and cyclophosphamide, PAC cisplatin, adriamycin and cyclophosphamide.
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PFTC risk [3-5]. High parity has been reported to be pro-
tective [6], and a history of pregnancy and the use of oral
contraceptives decreases the PFTC risk significantly [7,8].
It has been reported that there is no statistically significant
correlation between PFTC and age, race, weight, education
level, pelvic inflammatory disease, infertility, previous hys-
terectomy, endometriosis, lactose intolerance, or smoking
[7,9-11]. Meng et al. [12] found a fivefold higher bilateral
occurrence in infertile patients than in fertile patients, and
Clayton et al. [13] reported a better prognosis in nullipar-
ous women.
In the past, because the incidence of PFTC is fairly
low, and because there were no standard diagnostic and
staging criteria available, previous publications in this
area usually have been in the form of individual case re-
ports. In recent years, with the availability and wide
adoption of FIGO staging in our hospital, and the sig-
nificant enhancement of the accuracy of diagnosis, a
comprehensive retrospective analysis has been allowed
to help us gain a better understanding of the clinical and
pathological characteristics of PFTC.
In the present study, we summarize the clinical infor-
mation of 36 patients in one institute, and present a
thorough analysis of the factors that potentially influ-
enced survival.
Methods
Subjects and inclusion criteria
This retrospective study was approved by the ethnic
committee of Beijing Obstetrics and Gynecology Hos-
pital, Capital Medical University at 2008; the ethnic
committee approved related screening, treatment, data
collection and follow-up of these patients. All subjects
signed written informed consent form for using their
case data.
Participants were recruited from the patients diag-
nosed with genital malignancies from January 2001 to
July 2011 at the Beijing Hospital of Gynecology and Ob-
stetrics, which is affiliated with the Capital Medical Uni-
versity. According to the pathological standards of
FIGO, patients with fallopian tube carcinoma metastasis
were excluded. A total of 36 patients with pathologically
confirmed PFTC were included in the study.
General demographic data
As shown in Table 1, the mean age at onset was
57.2 years (range: 42 to 72 years). Among these cases, 25
were postmenopausal (69.4%), with a mean period since
menopause of 10.8 years (range: 1 to 22 years). There
were 9 cases of postmenopausal vaginal bleeding or ir-
regular vaginal bleeding (25.0%), 12 cases of vaginal dis-
charge (33.3%), 9 cases of abdominal distension or
abdominal pain (25.0%), 1 case of back pain, and 4 cases(11.1%) were asymptomatic with a pelvic mass being
discovered on physical examination. The remaining case
underwent uterine-rectal fossa tumor resection under
laparoscopy 3 years ago, with poorly differentiated car-
cinoma being pathologically confirmed. This patient
later underwent intraperitoneal chemotherapy with cis-
platin once, and upon thorough systemic examination,
no primary tumor was found. A year later, a type-B
ultrasonic check suggested the presence of a tumor
2 cm in diameter in the right accessories, and right fal-
lopian tube cancer was found after surgery. A total of 28
patients underwent a preoperative cervical ThinPrep cy-




One case underwent left oophorectomy and partial omen-
tum resection due to pelvic tumor adhesions. The same
patient, after three courses of chemotherapy, underwent
additional surgery and tumor debulking surgery. A total of
35 patients underwent uterine double oophorectomy, and
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(or) aortic lymph node dissection or sampling. A total of
35 patients underwent full or partial omental resection.
And, 20 patients underwent oncocytoreductive surgery.
The fallopian tube cancer surgical staging referenced the
FIGO (2000) staging criteria.
Chemotherapy
One patient underwent surgery after one course of neo-
adjuvant chemotherapy. Another 35 patients underwent
4 to 8 courses of postoperative chemotherapy; of these,
31 patients used taxol and cisplatin (TP) and 4 patients
used cisplatin and cyclophosphamide (PC) or cisplatin,
cisplatin, adriamycin and cyclophosphamide (PAC).
Radiotherapy
One patient underwent radiotherapy after six courses of
chemotherapy because of a postoperative residual aortic
lymph tumor, for which the tumor-absorbed dose (DT)
of extracorporeal pelvic irradiation field and extended ir-
radiation field combined was 40Gy. Other patients did not
undergo radiotherapy.
Statistical analysis
SPSS 18.0 software package (Illinois, USA) was used for
statistical analyses. The survival rate was calculated
using the Kaplan-Meier method. The Kaplan-Meier
method and Log-rank test were used in the single-factor
analysis of the correlation between the survival rate and
pathological staging of the surgery, diameter of an intra-
operative residual tumor being more than 1 cm, retro-
peritoneal lymph node metastasis, ovarian metastasis,
pathological classification, omentum metastasis and ele-
vated preoperative CA125. A COX proportional hazards
regression model was used in the multivariate analysis
of the correlation between the survival rate and an in-
traoperative residual tumor diameter >1 cm, ovarian
metastasis, omentum metastasis, and elevated preopera-
tive CA125. For P <0.05, the difference is considered
statistically significant.
Results and discussion
Most clinical characteristics are summarized in Table 2,
followed by the respective descriptions.
Preoperative screening
In the results of the cervical TCT examinations that
were attended by 28 patients, there was one case sug-
gesting CIN III staging, which was pathologically con-
firmed by colposcopy. Three cases was found with
atypical squamous cells, among which one case was con-
firmed by colposcopy as having inflammation; the other
two cases did not undergo colposcopy, and postoperative
pathology suggested cervicitis. Six patients underwentcurettage because of vaginal bleeding. One patient under-
went curettage twice due to postmenopausal vaginal
bleeding, suggesting necrotic tissues, and 10 months
after the second curettage, a pelvic mass was found,
which was confirmed by laparotomy. One patient
underwent curettage and uterine clear cell carcinoma
was suggested. For one patient, endometrial adenocarcin-
oma was suggested. Two patients underwent curettage
with no abnormal tissues being found. For one patient,
endometrium was not found during curettage.
Pathology analysis
In the 36 patients who received pathological examinations,
there was one patient with undifferentiated carcinoma,
one patient with undifferentiated and transitional cell car-
cinoma, and 34 patients with adenocarcinoma, among
whom 24 patients had pure adenocarcinoma and 10 pa-
tients had mixed type. Seven patients were complicated
with clear cell carcinoma, two patients were complicated
with endometrial cancer, and one patient was complicated
with transitional cell carcinoma. There were five patients
with moderately differentiated carcinoma, 29 patients with
poorly to moderately or simply poorly differentiated car-
cinoma, and 2 patients with undifferentiated carcinoma.
There was not a single case with highly differentiated car-
cinoma. There were 33 patients with unilateral fallopian
cancer; 3 patients with bilateral fallopian cancer; 13 pa-
tients with involvement of an ovary; 4 patients with uter-
ine transfer, including 3 patients with myometrial invasion
and one patient with endometrial involvement; 14 patients
with pelvic metastasis in the omentum; and 8 patients
with retroperitoneal lymph node metastasis. Ascites oc-
curred in 13 patients, with the volume of ascites ranging
from 100 ml to 8,000 ml. There were 19 patients positive
for ascites or peritoneal washings.
Surgical staging and residual tumor
Surgical pathological staging of the 36 patients has refer-
enced the FIGO (2000) standard, with 4 patients as stage
Ia, 5 patients as stage Ic, 2 patients as stage IIa, one pa-
tient as stage IIb, 5 patients as stage IIc, 2 patients as
stage IIIb, and 17 patients as stage IIIc. Early stages ac-
count for 47.2% of all patients. For intraoperative re-
sidual tumors, there were 18 patients with a residual
tumor visible to the naked eyes, with 7 patients having a
residual tumor with a diameter greater than 1 cm and
11 patients having a residual tumor with a diameter less
than 1 cm. There were 14 patients without residual tu-
mors visible to the naked eyes and 4 patients with no de-
scriptions of residual tumors in their surgical records.
CA125 examination as tumor marker
The normal reference value of CA125 is greater than
35 kU/L. There were 33 patients who underwent
Table 2 Summary of clinical characteristics
Clinic indexes Data
Preoperative screening:
28 preoperative cervical TCT 1 CIN stage III
3 with atypical squamous cells
1 inflammation
2 cervicitis
6 curettage 1 with necrotic tissues and pelvic mass
1 uterine clear cell carcinoma
1 endometrial adenocarcinoma
2 no abnormal tissues
1 endometrium not found
Pathology:
Type: 1 undifferentiated carcinoma





Complication: 7 complicated with clear cell carcinoma
2 complicated with endometrial cancer
1 complicated with transitional cell
carcinoma
Differentiation: 5 moderately differentiated
29 poorly to moderately, or simply
poorly, differentiated
2 undifferentiated
Sites: 33 unilateral fallopian cancer
3 bilateral fallopian cancer
13 with involvement in ovary
4 with uterine transfer
3 with myometrial invasion
1 with endometrial involvement
14 with pelvic metastasis in omentum
8 with retroperitoneal lymph node
metastasis
Surgical Staging:





Advanced Stage: (52.8%) 2 stage IIIb
17 stage IIIc
Intraoperative residual tumor: 18 with residual tumor
7 with diameter more than 1 cm
11 with diameter less than 1 cm
Table 2 Summary of clinical characteristics (Continued)
14 without residual tumor
4 without records













2 live with tumor
Sites of relapse: 1 on vaginal stump
4 with pelvic relapse
4 with peritoneal relapse
3 with significantly elevated CA125 yet
no lesions found
Abbreviation: CIN, cervical intraepithelial neoplasia.
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ranging from 11.7 to 7,600.0 kU/L. Among these 33
patients, 19 had elevated preoperative CA125, includ-
ing 2 patients who were stage Ic, 3 patients who were
stage IIc, one patient who was stage IIIb and 13 pa-
tients who were stage IIIc. For patients in the advanced
stages, there were five cases without elevated CA125.
Adjuvant treatment
One patient with an intraoperative residual tumor less
than 2 cm in diameter underwent surgery after one course
of neoadjuvant chemotherapy. There were 35 patients who
underwent four to eight courses of postoperative chemo-
therapy; of these patients, 31 used TP, and 4 used cisplatin
and cyclophosphamide (PC) or cisplatin, PC and cyclo-
phosphamide (PAC). There were 33 patients assessable for
clinical efficacies, with general efficacy of adjuvant treat-
ment reaching 87.9%. One patient underwent radiotherapy
after six courses of chemotherapy due to the presence of a
postoperative residual aortic lymph tumor, for which the
tumor-absorbed dose (DT) of extracorporeal pelvic irradi-
ation field and extended irradiation field combined was 40
Gy. Other patients did not undergo radiotherapy.
Follow-up and relapse
Follow-up began from the month of the diagnosis and
ended in December 2013. The average follow-up period
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There were four cases of drop-out due to loss of contact,
accounting for 11.1% of the patients. During follow-up,
there were 12 patients (33.3%) with relapse or metasta-
sis, 10 patients who died of cancer, and 2 patients who
have lived with the tumor. The time of relapse or metas-
tasis varied from 1 to 39 months after chemotherapy.
Sites of relapse are described as follows: one patient
showed relapse on the vaginal stump, four patients
showed pelvic relapse, four patients showed peritoneal
relapse, and three patients showed relapse with signifi-
cantly elevated CA125 but without specific lesions being
found.
Survival analysis
All the survival analyses were summarized in Figure 1.
We did survival analysis based on different clinical char-
acteristics, including with or without residual tumor,
with or without greater omentum metastasis, preopera-
tive CA125 content, pathological staging and ovarian
metastasis. There were 10 cases of death during the
follow-up period, among whom was one patient in the
Ic stage, one patient in the IIc stage, two patients in the
IIIb stage and 6 patients in the IIIc stage. The early mor-
tality rate (including stage I and II) was 11.8%, and ad-
vanced mortality rate (stage III) was 42.1%. The overallFigure 1 Five different survival analyses of 36 patients based on diffesurvival rates for 3 years and 5 years were 80.7% and
65.4%, respectively. Single-factor analysis showed that
pathological conditions of a residual tumor diameter
>1 cm (P <0.001), omentum metastasis (P = 0.003),
ovary metastasis (P = 0.004) and elevated preoperative
CA125 (P = 0.044) were associated with prognosis,
whereas pathological surgical staging (P = 0.069), retro-
peritoneal lymph node metastasis (P = 0.499), and
pathological classification (P = 0.183) were not associ-
ated with prognosis. Multifactor analysis showed that a
residual tumor diameter >1 cm (P = 0.019) and omentum
metastasis (P = 0.015) were associated with prognosis, and
were therefore the independent risk factors of prognosis.
Fallopian tube cancer is often asymptomatic, with often
atypical signs, and the ‘triad’ of vaginal discharge, ab-
dominal pain and pelvic mass. Abnormal vaginal bleed-
ing is also common, with other symptoms including
lower abdominal discomfort and abdominal distension.
It is reported that PFTC accounts for 0.75 to 1.2% of the
malignant tumors of the female reproductive system
[14-16]. In our study, results show that the average age
of onset is 57.2 years old (ranging from 42 to 72 years
old), which is consistent with previous reports of
53 years old [17] and 54.6 years old [18,19]. Our study
shows that 25 patients were postmenopausal (69.4%),
which is consistent with reported data [17]. Thus, werent clinical characteristics.
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prone to this disease. There were four patients (11.1%)
who were asymptomatic, yet had a pelvic mass that was
found during medical examination, suggesting that this
disease has an insidious onset. The clinical manifesta-
tions of fallopian tube carcinoma are somewhat hetero-
geneous, and the incidence rate is rather low; thus, the
preoperative misdiagnosis rate is high. In this study, 28
patients underwent cervical TCT examination, with
only 1 case being identified as CIN grade III, whereas
other patients had not shown any abnormal manifesta-
tions. Six patients underwent curettage, with only two
cases suggesting endometrial cancer. These results sug-
gest that preoperative TCT and curettage can exclude
other gynecological malignant tumors, such as cervical
cancer or endometrial cancer, but they do not help in
the diagnosis of PFTC, which is consistent with the
FIGO guidance [20].
Because the oviduct is very close to the ovaries and
uterus, it is sometimes difficult to identify primary le-
sions in patients with advanced carcinoma. In patients
with fallopian tube cancer, the ovaries and endometrium
can be normal, or they can also have tumor spread to
them because of the close lymphatic communication
among the three; but, the sizes of the tumor in ovaries
and endometrium would be smaller than the tumor in
the fallopian tube. The patients in our research were
classified according to the WHO standard classification:
5 patients with moderately differentiated carcinoma, 29
patients with moderately to poorly or simply poorly dif-
ferentiated carcinoma, and 2 patients with undifferenti-
ated carcinoma. There were no patients with highly
differentiated carcinoma according to this classification.
Previous studies [14-16] reported that up to 80.6% of the
patients sampled were of poorly differentiated carcin-
oma, and patients with highly differentiated carcinoma
only account for 2.9% of the sample. Yu et al. [21] re-
ported that patients with low differentiation accounted
for 72.7% of the patient sample, moderate differentiation
27.3% and no patient with high differentiation. Our
study is consistent with previous reports, suggesting that
carcinoma that is less differentiated is more commonly
seen in PFTC. Rabczynski et al. reported that most pa-
tients with postoperative mortality were pathologically
confirmed as having poorly differentiated PFTC [22]. But
our study shows that in the 36 patients, 29 patients
(80.6%) had moderately to poorly or simply poorly differ-
entiated carcinoma, accounting for the vast majority of
the patient sample. Although statistical analysis showed
no correlation between pathological classification and
prognosis, this might be because of the small number
of poorly differentiated cases. The most common site
of extrapelvic metastasis is the omentum, and in our
study, there were 14 patients with omentum metastasis.Statistical analysis showed that omentum metastasis
and ovarian metastasis are correlated with prognosis,
suggesting that the prognosis is rather poor for patients
with advanced carcinoma. There were eight patients
with retroperitoneal lymph node metastasis, but this was
not correlated with prognosis.
The normal reference value of CA125 is greater than
35 kU/L. Previous studies demonstrated that PFTC pa-
tients have elevated preoperative CA125 [23]. In our
study, 33 patients were preoperatively tested for CA125,
with results ranging from 11.7 to 7,600.0 kU/L, and
among these were 19 patients (57.6%) who had elevated
preoperative CA125. There were five advanced patients
who did not show elevated CA125 after medical testing.
In our research, statistical analysis showed that an ele-
vated preoperative CA125 is correlated with prognosis,
and a decreased CA125 during treatment is correlated
with clinical efficacy. There was a significant elevation in
CA125 during relapse and progression of disease. Previous
research indicates that the serum CA 125 level adequately
defines the response to chemotherapy and displays good
sensitivity and specificity characteristics during the follow-
up of patients with PFTC [23].
Current treatment of fallopian tube cancer is mostly
mimicking the treatment of ovarian cancer, with surgery
as the major clinical arrangement, and where conservative
operation is not a recommended practice [20]. For in-
stance, there were two patients in our study who showed
only hydrosalpinx during the surgery, which was patho-
logically confirmed as indicating a malignant tumor post-
operatively. In those patients for whom first surgery is not
radical enough, a second surgical staging or cytoreductive
surgery should be considered. Multivariate analysis showed
that the pathological conditions of an intraoperative re-
sidual tumor diameter >1 cm (P = 0.019) and omentum
metastasis (P = 0.015) are correlated with prognosis, and
were the independent risk factors of prognosis. The FIGO
guidance has suggested that the postoperative procedures
of PFTC are basically of the same principle with those of
the ovarian cancer (That is, patients at stage I who were
pathologically highly differentiated do not necessarily have
to go through adjuvant chemotherapy) [20]. But clinically,
patients of this kind are very rare; thus, the majority of pa-
tients have to settle on a plan of paclitaxel combined with
platinum. Our study showed that there were 33 patients
assessable for clinical efficacy after postoperative chemo-
therapy, suggesting a general clinical efficacy for chemo-
therapy of 87.9%. Many patients still have significantly
elevated CA125 after cytoreductive surgery, which later
drops back down to normal after chemotherapy and re-
mains at the normal level if no relapse or metastasis oc-
curs. Thus, the CA125 level during the postoperative
follow-up period is of great significance to the prediction
of relapse and metastasis.
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56.3% with a total of 64 patients involved. Other authors
have reported that the 3-year and 5-year survival rates of
PFTC patients were 87.3% and 65.2%, respectively [18].
Previous studies reported that the 5-year survival rates
for PFTC patients of stage I, II, III and IV were 66.7%,
50.0%, 36.0% and 0, respectively. Our study reports that
the overall survival rates of PFTC patients for 3-year and
5-year length are 80.7% and 65.4%. In our research, sin-
gle factor analysis showed that the pathological condi-
tion of intraoperative residual tumor diameter >1 cm
was correlated with prognosis, which is consistent with
previous research [19].Conclusions
Although single-factor analysis showed that surgical
pathological staging was not correlated with prognosis,
the mortality rate of advanced cases (stage III) (42.1%)
was significantly higher than early cases (11.8%). Our re-
search also showed that omentum metastasis and ovarian
metastasis were correlated with prognosis, suggesting that
the survival potential of advanced cases seems gloomy.
This is evidenced in the report by Tulunay [24]. Multivari-
ate analysis showed that the pathological conditions of an
intraoperative residual tumor diameter >1 cm (P = 0.019)
and omentum metastasis (P = 0.015) were correlated with
prognosis, and that these were independent risk factors of
prognosis. Yu et al. [21] suggested that the 3-year and
5-year survival rates of those who had received surgical
staging were higher than for those who had not received
surgical staging. The earlier the surgery, the more radical
the results can be. Thus, early diagnosis and early treat-
ment are the key factors to improving prognosis.
To summarize, the incidence of PFTC is rather low,
and its clinical manifestations are rather heterogeneous;
thus, it is difficult to confirm pathologically before surgery.
With the wide adoption of FIGO (2000) staging, the clin-
ical understanding of PFTC becomes clearer and its treat-
ments are increasingly standardized. Whether or not one
should carry out a radical cytoreductive surgery, which in-
cludes the excision of all primary tumors and metastases,
is of critical importance. And, postoperative chemotherapy
is an important adjuvant treatment. With these practices
standardized, the survival potential of PFTC can be greatly
enhanced.Abbreviations
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